Clinical trial
Safety Study of Apixaban in Recent Acute Coronary Syndrome
NCT00313300 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00313300 |
|---|---|
| Title | Safety Study of Apixaban in Recent Acute Coronary Syndrome |
| Official title | A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome. |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Coronary Syndrome (ACS) |
| Intervention type | Drug |
| Interventions | Apixaban, Placebo |
| Enrollment | 1,741 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | Dec 30, 2015 |
| Countries | Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Poland, Russia, Spain, Sweden and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: